Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 17/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.63 |
| ▸ | HRH2 | P25021 | 2/20 | 0.63 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775760 | 1.00 | HRH4 (1.00) | HRH4HRH3HRH2PRMT5WDR77 | |
| SCHEMBL1774588 | 1.00 | HRH4 (1.00) | HRH4HRH3HRH2PRMT5WDR77 | |
| SCHEMBL1774378 | 0.93 | HRH4 (0.87) | HRH4HRH3HRH2IL1BNLRP3 | |
| SCHEMBL1775451 | 0.93 | HRH4 (0.86) | HRH4HRH3HRH2PRMT5WDR77 | |
| SCHEMBL1773531 | 0.80 | HRH4 (0.69) | HRH4HRH3HRH2 | |
| SCHEMBL1775084 | 0.80 | HRH4 (0.69) | HRH4HRH3HRH2 | |
| SCHEMBL18672879 | 0.78 | HRH4 (0.64) | HRH4HRH3HRH2PRMT5WDR77 | |
| SCHEMBL1775487 | 0.78 | HRH4 (1.00) | HRH4HRH3HRH2 | |
| SCHEMBL1774042 | 0.78 | HRH4 (1.00) | HRH4HRH3HRH2 | |
| SCHEMBL1775292 | 0.78 | HRH4 (1.00) | HRH4HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885HRH3 187/4885HRH2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.